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Pharmacy-based Interventions to Reduce Primary
Medication Nonadherence to Cardiovascular Medications
Michael A. Fischer, MD, MS,* Niteesh K. Choudhry, MD, PhD,* Katsiaryna Bykov, PharmD, MS,*
Gregory Brill, BA,* Gregory Bopp, MS,w Aaron M. Wurst, BS,w and William H. Shrank, MD, MSHS*w
Background: Primary medication nonadherence (PMN) occurs
when patients do not fill new prescriptions. Interventions to reduce
PMN have not been well described.
Objectives: To determine whether 2 pharmacy-based interventions
could decrease PMN.
Design: Two sequential interventions with a control group were
evaluated after completion. The automated intervention began in
2007 and consisted of phone calls to patients on the third and
seventh days after a prescription was processed but remained un-
purchased. The live intervention began in 2009 and used calls from
a pharmacist or technician to patients who still had not picked up
their prescriptions after 8 days.
Subjects: Patients with newly prescribed cardiovascular medi-
cations received at CVS community pharmacies. Patients with
randomly selected birthdays served as the control population.
Measures: Patient abandonment of new prescription, defined as not
picking up medications within 30 days of initial processing at the
pharmacy.
Results: The automated intervention included 852,612 patients and
1.2 million prescriptions, with a control group of 9282 patients and
13,178 prescriptions. The live intervention included 121,155
patients and 139,502 prescriptions with a control group of
2976 patients and 3407 prescriptions. The groups were balanced by
age, sex, and patterns of prior prescription use. For the automated
intervention, 4.2% of prescriptions were abandoned in the inter-
vention group and 4.5% in the control group (P> 0.1), with no
significant differences for any individual classes of medications.
The live intervention was used in a group that had not purchased
prescriptions after 8 days and thus had much higher PMN. In this
setting 36.9% of prescriptions were abandoned in the intervention
group and 41.7% in the control group, a difference of 4.8%
(P < 0.0001). The difference in abandoned prescriptions for anti-
hypertensives was 6.9% (P< 0.0001) but for antihyperlipidemics
was only 1.4% (P> 0.1).
Conclusions: Automated reminder calls had no effect on PMN.
Live calls from pharmacists decreased antihypertensive PMN
significantly, although many patients still abandoned their
prescriptions.
Key Words: medication adherence, cardiovascular medications,
adherence interventions
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Nonadherence to chronic medications contributes tomorbidity, mortality, and avoidable health care costs,
estimated up to $290 billion a year in the United States.1
Evaluations of the rates2,3 and predictors4–8 of nonadherence
have been conducted, and numerous interventions have been
implemented to improve medication adherence.9–12 Histor-
ically, little has been known about how often patients are
written prescriptions but fail to ever fill the first one—known
as primary medication nonadherence (PMN). With the ad-
vent of electronic prescribing, researchers have been able to
link e-prescriptions to prescription claims records and have
found PMN in community settings of 22%–28%.13,14 Studies
in closed health care systems have found slightly lower rates
of PMN (15%–26%), although the problem is still sub-
stantial.15–17
Once PMN can be identified and measured, the chal-
lenge is to identify interventions specifically targeting PMN.
Systematic reviews of the adherence literature indicate that
community pharmacists can play an important role.10,18
Earlier research analyzed prescriptions abandoned at com-
munity pharmacies, a specific subset of PMN, and found
important patient and prescription-level characteristics as-
sociated with failure to pick up a prescription.19 Accord-
ingly, strategies using community pharmacists to reduce new
prescription abandonment could represent an important ap-
proach for addressing PMN. We evaluated 2 interventions
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implemented by a large pharmacy chain to reduce aban-
donment of new prescriptions for cardiovascular medi-
cations; an initial intervention using automated reminder
phone calls to patients and a second intervention using per-
sonal phone calls from pharmacists.
METHODS
Overview
CVS designed and implemented 2 interventions to
reduce abandonment of new prescriptions for cardiovascular
medications. The interventions were conducted before in-
volvement of the academic research team. For new inter-
ventions CVS routinely designates a random subset of
patients not to receive the intervention. After both inter-
ventions had been concluded, the research team agreed with
CVS-Caremark to obtain data for an analysis of both inter-
ventions.
Population
The service was provided to all patients who used CVS
community pharmacies except those born on a small subset
of randomly selected birthdays. Control patients received
usual care. We evaluated patients who used CVS pharmacies
and were also insured by Caremark, a large national phar-
macy benefits manager, so that we could use Caremark
claims data to more completely assess a patient’s medication
use subsequent to the intervention regardless of where a
prescription was filled.
Interventions
Automated Intervention
In 2007, CVS community pharmacies implemented a
nationwide intervention to reduce the portion of PMN ac-
counted for by abandonment of new prescriptions. This
specific element of PMN was defined by any prescription
that was received and processed at the pharmacy, but not
purchased by the patient. Patients received automated phone
calls on days 3 and 7 after the prescription was processed but
remained unpurchased. The calls reminded patients that their
prescription was ready and encouraged them to pick it up.
Patients with four randomly selected birthdays served as the
control population for this intervention.
Live Intervention
In 2009, CVS community pharmacies began a program
in which they identified patients who had not purchased a
prescription 8 days after it was bottled, even after receiving
automated calls on days 3 and 7. A pharmacist or technician
called these patients to better understand barriers to medi-
cation adherence and provide counseling and solutions to
encourage appropriate medication use. Messaging included
education about the importance of treatment, suggestions
about lower cost options when relevant, and efforts to engage
and motivate patients to adhere to therapy. Records indicated
which patients were selected to receive the intervention, but
data were not recorded on whether pharmacists or techni-
cians left a message or actually spoke with patients, or on
the content of conversations. Patients with eight randomly
selected birthdays served as the control population for this
intervention.
Data
New prescriptions for cardiovascular medications
(antihypertensives, antihyperlipidemics, antiarrhythmics, ni-
trates, digoxin) received at CVS community pharmacies
were identified. The time window for prescriptions was from
January 1, 2008 to November 30, 2008 for the automated
intervention and from January 1, 2010 to November 30, 2010
for the live intervention. Transaction data from the CVS
community pharmacies were linked with prescription claims
data from Caremark, from June 2007 to December 2008 for
the automated intervention analysis and from June 2009 to
December 2010 for the live intervention analysis. The link-
age of records was performed by CVS-Caremark, which
already had access to all patient information.
Claims data were used to identify previous and sub-
sequent dispensings at any pharmacy. The date the new
prescription was ordered and prepared at the pharmacy was
defined as the index date. A prescription was considered new
if there were no claims in the same therapeutic class
6 months before the index date. Patients without at
least 6 months of eligibility before the index date were ex-
cluded unless they had another prescription that satisfied the
inclusion criteria. Claims data for 30 days after the index
date were used to identify dispensing of any drug from the
TABLE 1. Automated Intervention: Patient Characteristics (At
the Time of the First Index Rx; Prior Use Assessed Over the
Period of 6mo Before Index Date)
Characteristic
Intervention Group
(N=852,612)
Control Group
(N=9282)
Total number of index
prescriptions
1,226,834 13,178
Age in years, mean (SD) 59.1 (16.2) 59.3 (16.2)
Age group, n (%)
0–17 8219 (1.0) 91 (1.0)
18–34 45,952 (5.4) 475 (5.1)
35–49 179,432 (21.0) 1951 (21.0)
50–64 303,009 (35.5) 3275 (35.3)
65 and older 316,000 (37.1) 3490 (37.6)
Female sex, n (%) 463,577 (54.4) 5032 (54.2)
Mean no. index
prescriptions per patient
1.44 1.42
Prior use of medications (%)
Statins 21.6 22.3
Antihypertensive meds 54.0 53.8
Antidepressants 18.6 18.3
Antipsychotics 3.2 3.3
Inhaled asthma/COPD
meds
10.3 10.6
Oral diabetes medication 15.0 15.1
Hydrocodone-APAP 14.4 14.4
Insulin 5.1 5.3
Osteoporosis
medications
6.0 6.1
Proton pump inhibitors 18.0 17.8
Thyroid medications 10.4 10.4
Warfarin 5.3 5.1
Mean no. different
medications
7.69 7.63
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same therapeutic class as the index prescription at any
pharmacy. Patient characteristics were assessed on the index
date and during the 6-month prior period. Before data were
provided to the research team all identifiers were removed.
The study was approved by the Institutional Review Board at
the primary author’s home institution.
Outcome
The primary outcome was prescription abandonment,
defined as a reversed Caremark claim for a new cardio-
vascular prescription with no subsequent claim for a medi-
cation from the same therapeutic class within 30 days
following the index date.
Analyses
Patient characteristics at baseline were assessed using
descriptive statistics. We compared proportions of pre-
scriptions abandoned in the intervention group and controls.
The unit of analysis was the prescription and proportions
were expressed as number of prescriptions abandoned div-
ided by total prescriptions initially processed by the phar-
macy. We used a generalized linear model with logit link
function to adjust for clustering of prescriptions within pa-
tients. Results were further stratified by medication classes.
All analyses were performed using SAS software, version 9.3
(SAS Institute, Cary, NC).
Role of the Funding Source
The research was funded by the National Association
of Chain Drug Stores Foundation. Study design, conduct, and
reporting were determined independently by the research
team.
RESULTS
The automated intervention included 852,612 patients
and 1.2 million prescriptions, with a control group of 9282
patients and 13,178 prescriptions. The live intervention in-
cluded 121,155 patients and 139,502 prescriptions with a
control group of 2976 patients and 3407 prescriptions. Control
and intervention groups were balanced by age, sex, and prior
prescription use (Tables 1 and 2). Most patients received 1 new
cardiovascular prescription during the study period, but a
substantial fraction received 2 or more (Table 3).
Table 4 shows the main results for the automated in-
tervention. The proportion of abandoned prescriptions was
4.2% in the intervention group and 4.5% in the control group
(P= 0.23). For antihypertensives the proportion of aban-
doned prescriptions was 3.7% in the intervention group and
4.1% in the control group (P= 0.06), whereas for anti-
hyperlipidemics the proportions were the same (6.0%). The
intervention did not have a significant impact on abandoned
prescriptions for other CV medications.
The live intervention was used in patients who had
received the automated intervention but not purchased
prescriptions after 8 days. Table 5 shows that in this setting
the proportion of abandoned prescriptions was 36.9% in the
intervention group and 41.7% in the control group, a difference
of 4.8% (P<0.0001). The difference for antihypertensives was
6.9% (P<0.0001) but for antihyperlipidemics was only 1.4%
(P=0.25). Inclusion of prescriber characteristics, copayment,
median income for the patient’s zip code or patient demo-
graphics in multivariate models did not substantively change
any findings.
TABLE 2. Pharmacist Intervention: Patient Characteristics (At
the Time of the First Index Rx; Prior Use Assessed Over the
Period of 6mo Before Index Date)
Characteristic
Intervention Group
(N=121,155)
Control Group
(N=2976)
Total number of index
prescriptions
139,502 3407
Age in years, mean (SD) 56.6 (14.3) 57.3 (14.4)
Age group, n (%)
0–17 0 0
18–34 6714 (5.5) 154 (5.2)
35–49 30,997 (25.6) 720 (24.2)
50–64 51,860 (42.8) 1276 (42.9)
65 and older 31,584 (26.1) 826 (27.8)
Female sex, n (%) 63,602 (52.5) 1593 (53.5)
Mean no. index
prescriptions per patient
1.15 1.14
Prior use of medications (%)
Statins 17.7 18.1
Antihypertensive meds 46.3 46.1
Antidepressants 19.2 19.3
Antipsychotics 2.7 2.6
Inhaled asthma/COPD
meds
9.4 9.4
Oral diabetes medication 17.8 17.8
Hydrocodone-APAP 15.4 15.7
Insulin 6.5 6.3
Osteoporosis
medications
3.5 3.5
Proton pump inhibitors 16.7 17.3
Thyroid medications 10.1 10.6
Warfarin 4.0 4.9
Mean no. different
medications
6.63 6.65
TABLE 3. Patients and Number of New Cardiovascular
Prescriptions in the Cohort
N (%)
Intervention Control
Automated intervention
Patients 852,612 9282
Prescriptions 1,226,834 13,178
Patients with 1 index Rx 608,159 (71.3) 6681 (72.0)
Patients with 2 index Rxs 161,752 (19.0) 1756 (18.9)
Patients with 3 index Rxs 52,517 (6.2) 545 (5.9)
Patients with 4+ index Rxs 30,184 (3.5) 300 (3.2)
Mean index Rxs per patient 1.44 1.42
Live intervention
Patients 121,155 2976
Prescriptions 139,502 3407
Patients with 1 index Rx 106,612 (88.0) 2631 (88.4)
Patients with 2 index Rxs 11,671 (9.6) 282 (9.5)
Patients with 3 index Rxs 2178 (1.8) 46 (1.6)
Patients with 4+ index Rxs 694 (0.6) 17 (0.6)
Mean index Rxs per patient 1.15 1.14
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DISCUSSION
We evaluated 2 pharmacy-based interventions de-
signed to reduce PMN for cardiovascular medications. We
found that automated calls from the pharmacy did not sig-
nificantly reduce prescription abandonment. Adding live
telephone calls if patients still had not picked up their new
prescriptions did reduce abandonment by almost 5%. This
effect was driven by increased filling of antihypertensive
medications—there was no effect of the live intervention on
antihyperlipidemics or other cardiovascular medication
classes. This difference may indicate that patient decisions
about whether to fill antihypertensive medications are more
amenable to intervention than such decisions for other
medications. Our data cannot indicate reasons for this dif-
ference, although possible explanations could include patient
perceptions of the seriousness of hypertension versus hy-
perlipidemia. Future qualitative research assessing patient
reasons for PMN, degree of openness to interventions, and
reasons for these perceptions could inform new inter-
ventions.
As PMN has not been widely measured until recently,
there is limited prior literature on the impact of interventions
to increase primary adherence to newly prescribed medi-
cations. DeRose et al17 evaluated automated telephone calls
and follow-up letters to 2606 patients who had not filled a
new statin prescription, finding a significant increase in statin
filling with the intervention, very different from our results.
The intervention studied by DeRose and colleagues took
place in the Kaiser Permanente system, a large integrated
health care system and the outreach to patients was from
their health care provider, and included multiple modalities,
whereas the intervention that we studied was initiated by the
pharmacy to which the prescription was sent.
There are important limitations to consider when in-
terpreting these findings. Patients may have filled pre-
scriptions that were not captured in the claims data—for
example, if patients paid cash for a prescription or had ad-
ditional drug insurance coverage. This would lead us to
overestimate prescription abandonment and might obscure
potential impacts of the intervention. Given that we did not
TABLE 4. Automated Intervention: Prescription Abandonment, Total and by Drug Class
Intervention Group Control Group
Drug Class* Total Rx Abandonedw % Total Rx Abandonedw % P**
All classes 1,226,834 51,890 4.2 13,178 596 4.5 0.23
Antihypertensives 814,187 29,683 3.7 8718 361 4.1 0.06
ACEI/ARBs 189,053 8071 4.3 2030 90 4.4 0.73
b-blockers 166,456 5201 3.1 1753 61 3.5 0.38
Ca channel blockers 102,119 3411 3.3 1050 38 3.6 0.62
Diuretics 220,186 6201 2.8 2396 87 3.6 0.02
Antiarrhythmics 11,336 296 2.6 138 2 1.5 0.40
Antihyperlipidemics 328,323 19,544 6.0 3504 210 6.0 0.93
Others 72,988 2367 3.2 818 23 2.8 0.50
*Antihypertensive combination products were only counted in the “antihypertensives” class category; therefore, the sum of the specific antihypertensive classes does not add up
to the category “antihypertensives”; “others” category includes digoxin, peripheral vasodilators, phosphodiesterase inhibitors, nitrates, and other antianginals.
wAbandoned are prescriptions for which no medication from the same therapeutic class (identified by the first 4 digits of the Generic Product Index) was purchased by a patient at
any pharmacy within 30 days following the index prescription processing.
**P values from generalized linear model adjusted for clustering of prescriptions within patients.
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
TABLE 5. Live Intervention: Prescription Abandonment, Total and by Drug Class
Intervention Group Control Group
Drug Class* Total Rx Abandonedw % Total Rx Abandonedw % P**
All classes 139,502 51,455 36.9 3407 1419 41.7 < 0.0001
Antihypertensives 82,373 29,106 35.3 1993 841 42.2 < 0.0001
ACEI/ARBs 21,600 7756 35.9 541 222 41.0 0.02
b-blockers 16,276 5645 34.7 400 176 44.0 < 0.001
Ca channel blockers 9726 3466 35.6 220 79 35.9 0.93
Diuretics 18,525 6179 33.4 426 182 42.7 < 0.0001
Antiarrhythmics 667 239 35.8 15 5 33.3 0.84
Antihyperlipidemics 51,254 20,180 39.4 1284 524 40.8 0.25
Others 5208 1930 37.1 115 49 42.6 0.22
*Antihypertensive combination products were only counted in the “antihypertensives” class category; therefore, the sum of the specific antihypertensive classes does not add up
to the category “antihypertensives”; “others” category includes digoxin, peripheral vasodilators, phosphodiesterase inhibitors, nitrates. and other antianginals.
wAbandoned are prescriptions for which no medication from the same therapeutic class (identified by the first 4 digits of the Generic Product Index) was purchased by a patient at
any pharmacy within 30 days following the index prescription processing.
**P values from generalized linear model adjusted for clustering of prescriptions within patients.
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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see an impact when we added copayments to the model we
do not think that cost-related nonadherence affected our
findings; prior studies have shown that cost is a factor in
medication nonadherence but with a relatively small absolute
impact.7,13,20 We did not have data on whether individual
pharmacies were calling patients before the intervention
start, or on the extent to which individual pharmacists
complied with live phone call protocols. Imbalance in the
randomly selected intervention and control groups could lead
to biased results, but Tables 1 and 2 show that the randomly
selected control population resulted in excellent com-
parability of the intervention and control groups. Only 6
months of preintervention claims data were available, so we
may have included patients who had used the index drugs
previously. We evaluated an intervention in a single com-
munity pharmacy chain and for only cardiovascular medi-
cations, which could limit the generalizability of our
findings.
Our results have important implications for clinical and
policy approaches to improving medication adherence. Au-
tomated reminder calls from pharmacies are used commonly,
but in this study they did not improve primary medication
adherence. We evaluated only newly prescribed medications;
automated calls may be useful for patients refilling existing
medications. Live intervention results were more promising;
on the basis of the changes in adherence that we observed, 15
live calls would yield 1 additional filled prescription for an
antihypertensive medication. The live intervention was for
patients who had not picked up prescriptions after 8 days
despite automated calls; whether the impact would differ if
the intervention were implemented sooner is not clear from
these data. The cost-effectiveness of this approach would
depend on the time required for each call and the long-term
clinical impact of improved adherence. Primary care clini-
cians, pharmacists, and insurers will need to consider these
results when designing new interventions targeting PMN.
Recent conclusions from the CBO that increased spending
for prescription drugs is offset by reduced health services
utilization highlight an important additional consideration
for risk-bearing providers such as accountable care organ-
izations or patient-centered medical homes.21
In conclusion, we analyzed 2 large, national pop-
ulations of patients and prescriptions who received inter-
ventions to improve primary medication adherence.
Although automated interventions did not improve adher-
ence, the addition of live interventions increased the filling of
new prescriptions for antihypertensives. Even with the pos-
itive changes with the addition of the live intervention, many
patients still abandoned their prescriptions at the pharmacy.
While pharmacy-based interventions can play an important
role in improving medication adherence, this study makes
clear that truly improving adherence, and thus patient out-
comes, is likely to require multiple interventions targeting
the different elements of this complex behavior.
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